Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICM-guided Rate Control in AF with HFpEF
NCT05745337Phase 1Recruiting
- Sponsor
- The University of Vermont
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metoprolol, diltiazem and verapamil in Atrial fibrillation (AFib) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by The University of Vermont. Primary endpoint: Exercise capacity at 6 months. Started Feb 2023; status: recruiting.
02
Drugs
metoprololdiltiazemverapamil
03
Conditions
Atrial fibrillation (AFib)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05745337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745337.